{"filings":[{"id":99040,"accession_number":"0000818479-26-000147","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dentsply Sirona Q1 adj EPS $0.27, down 39% YoY; net sales flat at $880M","event_type":"earnings","confidence":"high","bullets":["GAAP net loss per share ($0.05); adjusted EPS $0.27 vs $0.44 in Q1 2025.","Net sales $880M (+0.1% as reported); constant currency sales declined 6.7% YoY.","GAAP gross margin 48.5% vs 53.0% a year ago; adjusted EBITDA margin 14.7% vs 19.0%.","Orthodontic & Implant Solutions sales down 8.1% as reported; Wellspect Healthcare up 15%.","Reiterated 2026 outlook: net sales $3.5B-$3.6B, adj EPS $1.40-$1.50."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":880000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114835,"accession_number":"0000818479-26-000072","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dentsply Sirona Q4 net loss $146M on $144M impairments; eliminates dividend, guides FY2026 adj EPS $1.40-$1.50","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $961M (+6.2% reported, +2.5% constant currency); reported diluted EPS ($0.74) from $144M impairments.","FY2025 net sales $3.68B (-3.0%), adjusted EPS $1.60. FY2026 guidance: sales $3.5-3.6B, adjusted EPS $1.40-1.50.","Restructuring plan approved: $55-65M charges, ~$120M annual savings, reinvested in growth initiatives.","Quarterly dividend eliminated; capital redeployed to debt retirement and share repurchases.","Appointed three new board members (Forbes, McKeon, Zurbay); new distribution agreements with Patterson, Benco, Burkhart, A-dec."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":3680000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114834,"accession_number":"0000818479-26-000058","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona appoints Forbes and McKeon to board; Deese retiring","event_type":"leadership","confidence":"high","bullets":["James Forbes (former Morgan Stanley vice chairman) and Brian McKeon (former IDEXX CFO) join Board effective Feb 27, 2026.","Forbes will serve on Compensation & Human Capital Committee; McKeon on Audit/Finance and Science/Technology Committees.","Board size increased from 11 to 13 as part of ongoing refreshment to support Return-to-Growth plan.","Willie Deese will not stand for re-election at 2026 annual meeting; no disagreement with company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114833,"accession_number":"0000818479-26-000043","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dentsply Sirona renews U.S. dental technology distribution agreement with Patterson Dental","event_type":"other_material","confidence":"high","bullets":["Renewed non-exclusive agreement covers Dentsply Sirona's full portfolio including CEREC, Primescan, Axeos, and Orthophos systems.","Partnership aims to accelerate adoption of integrated technologies and expand access to dental professionals across the U.S.","Quotes from Dentsply Sirona CCO Aldo Denti and Patterson Dental President Patrik Eriksson highlight commitment to growth and innovation.","Agreement effective January 14, 2026; underscores decades-long collaboration between the two companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114832,"accession_number":"0000818479-26-000024","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona adds former Patterson CEO Zurbay to Board; creates Growth and Value Creation Committee","event_type":"leadership","confidence":"high","bullets":["Donald Zurbay appointed to Board effective Jan 10, 2026; former Patterson CEO/CFO and St. Jude Medical CFO.","Board expanded from 10 to 11 members; Zurbay joins Audit and Finance Committee.","Board established Growth and Value Creation Committee to oversee Return-to-Growth action plan, co-chaired by Chairman & CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131221,"accession_number":"0000818479-25-000300","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Dentsply Sirona amends debt covenants; new leverage ratios step down to 3.50x, restricts dividends","event_type":"debt","confidence":"high","bullets":["New Total Leverage Ratio covenant: cannot exceed 4.25x (Q4 2025–Q2 2026) stepping down to 3.50x (Q3 2027+).","New Senior Leverage Ratio covenant: cannot exceed 3.25x (same period) stepping down to 2.50x (Q3 2027+).","Restricted Payments (dividends, buybacks) prohibited subject to specified exceptions.","EBITDA addback cap for efficiency initiatives: up to $75M aggregate for Q4 2025 through Q4 2026.","Interest rate adjustments triggered if total leverage ratio exceeds specified thresholds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131220,"accession_number":"0000818479-25-000281","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"DENTSPLY SIRONA appoints Michael Pomeroy as interim CFO; CEO remains principal financial officer","event_type":"leadership","confidence":"high","bullets":["Michael Pomeroy appointed interim CFO effective November 25, 2025.","CEO Daniel Scavilla will continue as principal financial officer until a permanent CFO is named.","Pomeroy most recently served as interim CFO of Highridge Medical (Feb-Sep 2025).","Prior roles include EVP and CFO of Icahn Automotive Group (2022-2024) and VP/CFO of RGIS.","Permanent CFO search is ongoing; Pomeroy's appointment is temporary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131215,"accession_number":"0000818479-25-000267","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K/A","filed_at":"2025-11-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CFO Matthew Garth separation agreement: $1.2M in payments, equity forfeiture, restrictive covenants","event_type":"leadership","confidence":"high","bullets":["Matthew E. Garth's separation effective Nov 5, 2025; agreement signed Nov 7, 2025.","Severance: $1.2M in two $600k installments plus $32,430 for COBRA premiums.","Unvested equity awards forfeited except prorated portion (5/36ths) of May 30, 2025 PRSUs.","Receipt of payments contingent on release and compliance with restrictive covenants.","Outplacement services for 12 months provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131219,"accession_number":"0000818479-25-000254","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dentsply Sirona Q3 net sales down 5% to $904M; GAAP loss $2.14/share; cuts FY25 outlook","event_type":"earnings","confidence":"high","bullets":["Net sales $904M, down 5.0% as-reported, 8.0% constant currency; GAAP net loss per share ($2.14).","Adjusted EPS $0.37 vs $0.50 prior year, down 26.5%; adjusted gross margin 52.6% from 55.3%.","CFO Matt Garth departed; Aldo Denti named Chief Commercial Officer; Dustin Shields named Chief Transformation Officer Dec 1.","FY25 revised outlook: net sales $3.6B-$3.7B, constant currency decline 4%-5%, adjusted EPS ~$1.60.","Q3 goodwill impairment charge $263M net of tax ($1.31 per share)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":2719000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131218,"accession_number":"0000818479-25-000253","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Matthew Garth to depart Nov 5; CEO Scavilla takes interim CFO role","event_type":"leadership","confidence":"high","bullets":["Matthew E. Garth will leave as EVP and CFO effective November 5, 2025.","Departure not due to any disagreement on financial statements, controls, or operations.","Company has initiated a formal search process for a new CFO.","CEO Daniel T. Scavilla appointed interim principal financial officer for SEC filings.","No new compensatory arrangements entered for Scavilla in connection with interim role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131217,"accession_number":"0000818479-25-000203","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SEC concludes investigation of Dentsply Sirona without enforcement action","event_type":"regulatory","confidence":"high","bullets":["SEC's Division of Enforcement closed its investigation initiated May 2022.","No enforcement action recommended; company fully cooperated throughout.","Investigation related to financial reporting allegations from current/former employees.","Company views closure as a significant and favorable development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131216,"accession_number":"0000818479-25-000182","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"EVP, General Counsel & Secretary Richard Rosenzweig departs; becomes Special Legal Advisor","event_type":"leadership","confidence":"high","bullets":["Richard C. Rosenzweig ceases role as EVP, Corporate Development, General Counsel and Secretary effective Oct 3, 2025 by mutual agreement.","Rosenzweig transitions to non-officer Special Legal Advisor through March 4, 2026 with monthly fixed fee of $30,000.","Eligible for severance: $606,320 base salary, $454,740 target bonus, $32,309 COBRA, 2025 bonus, and accelerated vesting of one-time RSU grant.","After separation, will serve as independent contractor consultant for one year at $20,000/month.","Receives full 100% vesting of SERP deferred compensation; non-compete period begins Oct 3, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147810,"accession_number":"0000818479-25-000174","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dentsply Sirona awards $2M retention stock options to SVP/Chief Supply Chain Officer","event_type":"leadership","confidence":"high","bullets":["Retention grant of stock options with grant-date fair value of $2,000,000 to Tony Johnson, SVP and Chief Supply Chain Officer.","Options cliff-vest on third anniversary of grant date, subject to continuous employment.","Half of options priced at fair market value (FMV) on grant date; half at 110% of FMV.","Grant expected on second trading day after Q3 2025 10-Q filing; expires 10 years from grant date.","Award intended to retain Johnson following recent CEO/CFO transition and recognize his performance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147809,"accession_number":"0000818479-25-000167","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Dentsply Sirona Retains Wellspect Healthcare After Strategic Review, Ends Sale Process","event_type":"other_material","confidence":"high","bullets":["Strategic review of Wellspect begun Feb 2025 completed Sep 8, 2025; company decided to retain the business.","Wellspect is a leader in continence care with LoFric and Navina brands; mid-single digit organic sales growth in 2024.","CEO Dan Scavilla cited strong cash flow, untapped market potential, and a $2B addressable market for the decision.","Company conducted broad outreach and considered a sale but determined retention creates more stockholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147808,"accession_number":"0000818479-25-000152","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Dentsply Sirona Q2 net sales $936M (-4.9%); adjusted EPS $0.52 (+6.6%); appoints new CEO Dan Scavilla","event_type":"earnings","confidence":"high","bullets":["Net sales $936M, down 4.9% (down 6.7% constant currency); GAAP net loss ($45M) or ($0.22) per share.","Adjusted EPS $0.52 vs $0.49; adjusted EBITDA margin 21.1% vs 17.5% (14.6% growth).","Executed $550M debt offering; reaffirmed FY25 outlook.","Dan Scavilla appointed CEO effective Aug 1, 2025; Matt Garth as CFO effective May 30, 2025.","Byte sales had a 3.2% negative impact on constant currency sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":1815000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147807,"accession_number":"0000818479-25-000137","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona appoints Daniel Scavilla as CEO; preliminary Q2 sales ~$935M and adj. EPS $0.50-0.52","event_type":"leadership","confidence":"high","bullets":["Daniel Scavilla appointed President & CEO effective Aug 1, 2025, succeeding Simon Campion who departs July 31, 2025.","Preliminary Q2 net sales ~$935M and adjusted EPS expected between $0.50 and $0.52.","Company reaffirms 2025 outlook provided in May 8 earnings release.","Campion to receive severance per existing agreement, including SERP vesting and up to $90k in relocation/legal reimbursements.","Scavilla receives base salary $1.03M, target bonus 135%, initial equity grant ~$6.4M, and signing bonuses up to $1.75M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166509,"accession_number":"0001193125-25-140055","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Dentsply Sirona issues $550M of 8.375% junior subordinated notes due 2055, repays $435M bridge loan","event_type":"debt","confidence":"high","bullets":["Issued $550M aggregate principal of 8.375% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due September 12, 2055.","Interest rate: 8.375% through September 12, 2030, then resets to 5-year UST rate + 4.379% with an 8.375% floor.","Used proceeds to repay in full the outstanding $435M 364-day bridge loan facility, terminating it with no penalties.","Notes redeemable at par during 90 days before first reset date and on interest payment dates after first reset."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166508,"accession_number":"0001193125-25-136361","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Dentsply Sirona prices $550M 8.375% junior subordinated notes due 2055","event_type":"debt","confidence":"high","bullets":["$550M aggregate principal amount of 8.375% fixed-to-fixed reset rate junior subordinated notes due 2055.","Net proceeds ~$544.5M; expected close June 12, 2025, subject to customary conditions.","Interest fixed at 8.375% until Sep 12, 2030, then resets at 5yr UST + 4.379% with 8.375% floor.","Proceeds to repay existing $435M term loan and other short-term debt; general corporate uses.","Goldman Sachs sole book-runner; PNC, Commerz Markets, Truist, MUFG acting as co-managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166507,"accession_number":"0001193125-25-134427","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Dentsply Sirona amends credit agreements to add leverage covenant, increase ratio limit to 65%","event_type":"debt","confidence":"high","bullets":["New financial covenant: senior debt to capitalization must not exceed 60%.","Maximum allowable consolidated leverage ratio increased to 65%.","German subsidiary debt reclassified as permitted debt under a standalone basket.","Interest rate adjustments triggered if credit rating falls below investment grade.","Amendments affect revolving credit facility and three note purchase agreements; effective upon satisfaction of conditions precedent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166506,"accession_number":"0000818479-25-000086","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Dentsply Sirona appoints Matthew Garth as CFO, effective May 30, 2025","event_type":"leadership","confidence":"high","bullets":["Matthew Garth named EVP & CFO; previously CFO & CAO of Scotts Miracle-Gro.","Compensation: $800k base salary, 85% target bonus, annual equity grant of $2.75M.","Equity components: stock options ($687.5k), RSUs ($687.5k), PRSUs ($1.375M) with 3-year targets.","Nearly 30 years of financial leadership at Scotts, Minerals Technologies, and Alcoa.","No family relationships or material transactions disclosed; subject to non-compete and severance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166505,"accession_number":"0000818479-25-000080","cik":818479,"company_name":"DENTSPLY SIRONA Inc.","ticker":"XRAY","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"DENTSPLY SIRONA annual meeting elects all 11 directors; approves 11.26M share increase for incentive plan","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected with >94% of votes cast; broker non-votes of ~11.3 million.","Ratification of Deloitte as auditor for 2025: 187.6 million for, 0.4 million against.","Non-binding advisory vote on 2024 executive compensation approved: 170.9 million for, 4.9 million against.","Amendment to 2024 Omnibus Incentive Plan to increase shares by 11.26 million approved: 166.0 million for, 10.6 million against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}